Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GILD

Gilead Sciences (GILD)

Gilead Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GILD
DateTimeSourceHeadlineSymbolCompany
12/06/202409:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
12/06/202409:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
12/06/202409:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
12/06/202409:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
12/06/202409:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
12/06/202409:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
06/06/202418:30Business WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNANASDAQ:GILDGilead Sciences Inc
05/06/202416:00Business WireGilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
04/06/202400:00Business WireKite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNASDAQ:GILDGilead Sciences Inc
03/06/202423:00Business WireEncouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System LymphomaNASDAQ:GILDGilead Sciences Inc
02/06/202422:00Business WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
02/06/202422:00Business WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
01/06/202422:00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
01/06/202422:00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
31/05/202422:07Business WireEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024NASDAQ:GILDGilead Sciences Inc
31/05/202406:45Business WireGilead Provides Update on Phase 3 TROPiCS-04 StudyNASDAQ:GILDGilead Sciences Inc
22/05/202422:30Business WireGilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024NASDAQ:GILDGilead Sciences Inc
18/05/202422:30Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
15/05/202400:09Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyNASDAQ:GILDGilead Sciences Inc
10/05/202407:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202407:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202406:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
10/05/202406:05Business WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramNASDAQ:GILDGilead Sciences Inc
10/05/202405:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
10/05/202405:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
09/05/202406:58Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GILDGilead Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:GILD